Get the Stockscreener App
25.50
1.32%
-0.34
After Hours:
25.54
0.04
+0.16%
Capricor Therapeutics Inc stock is traded at $25.50, with a volume of 741.01K.
It is down -1.32% in the last 24 hours and up +4.08% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$25.84
Open:
$26.44
24h Volume:
741.01K
Relative Volume:
0.30
Market Cap:
$1.39B
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-30.72
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
-10.05%
1M Performance:
+4.08%
6M Performance:
+329.29%
1Y Performance:
+86.13%
1-Day Range:
$25.33
$26.58
1-Week Range:
$25.12
$28.45
52-Week Range:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
25.50 | 1.41B | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
CAPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Capricor (CAPR) Faces Challenges Amidst Stricter FDA Approval Pr - GuruFocus
Register: Aligning With the FDA on a Regulatory Pathway To Avoid Decision Day Surprises - BioSpace
(CAPR) Volatility Zones as Tactical Triggers - Stock Traders Daily
CAPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Unpacking The 82% Potential Upside - DirectorsTalk Interviews
Capricor Therapeutics (CAPR) Schedule 13G: Suvretta reports 6.6% stake - Stock Titan
A Look At Capricor Therapeutics (CAPR) Valuation As Key Deramiocel Phase 3 Milestones Advance FDA Review - simplywall.st
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference - Bitget
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Asianet Newsable
Q3 2025 Capricor Therapeutics Inc Earnings Call Transcript - GuruFocus
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Unveiling a 74% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
CAPR Stock Rallied Nearly 30% So Far This Week — Here’s The February FDA Catalyst Investors Are Betting On - Stocktwits
Capricor Therapeutics (NASDAQ:CAPR) Trading 12.2% HigherTime to Buy? - MarketBeat
GSA Capital Partners LLP Makes New $1.56 Million Investment in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Highbridge discloses 2.3% Capricor Therapeutics (CAPR) stake via warrants - Stock Titan
What’s the profit margin of Capricor Therapeutics IncEarnings Growth Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Aug PostEarnings: Whats the profit margin of Capricor Therapeutics IncForecast Cut & Reliable Price Action Trade Plans - baoquankhu1.vn
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: A 114% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Breakout Move: Whats the profit margin of Capricor Therapeutics Inc2025 Bull vs Bear & Weekly Momentum Stock Picks - baoquankhu1.vn
Why Capricor Therapeutics Inc. stock could see breakout soonEarnings Growth Summary & Long-Term Capital Growth Strategies - mfd.ru
How cyclical is Capricor Therapeutics Inc.’s revenue streamWeekly Trend Summary & Long-Term Capital Growth Strategies - mfd.ru
Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment - BioSpace
(CAPR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50-Day Moving AverageTime to Sell? - MarketBeat
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback - MSN
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
A Look At Capricor Therapeutics (CAPR) Valuation After Its New Shelf Registration Filing - Sahm
Phase III wins propel Capricor, Belite and DBV higher in December - BioWorld MedTech
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Capric - GuruFocus
Capricor Therapeutics, Inc. (CAPR): Uncovering the 124.68% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Oppenheimer reiterates Outperform rating on Capricor stock, maintains $54 target - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.7%Here's Why - MarketBeat
Does FDA’s No-New-Trial Stance on Deramiocel Shift the Bull Case for Capricor Therapeutics (CAPR)? - Sahm
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50 Day Moving AverageShould You Sell? - MarketBeat
(CAPR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
A Look At Capricor Therapeutics (CAPR) Valuation As FDA Advances Review Of Deramiocel BLA - Sahm
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’ - MSN
Tang Capital group reports 6.6% Capricor (NASDAQ: CAPR) ownership on Schedule 13G - Stock Titan
Highs Report: Whats the profit margin of Capricor Therapeutics IncBull Run & Weekly Stock Breakout Alerts - baoquankhu1.vn
Capricor Therapeutics, Inc. (CAPR): Investor Outlook On Promising 110% Upside Potential - DirectorsTalk Interviews
CAPR stock slides after FDA requests more data for genetic disorder therapy — what does retail think? - MSN
CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February - TradingView — Track All Markets
Does FDA’s HOPE-3 Data Request Clarify Deramiocel’s Regulatory Path For Capricor Therapeutics (CAPR)? - Sahm
Is FDA’s No-New-Trial Stance on Deramiocel Reshaping the Investment Case for Capricor Therapeutics (CAPR)? - Yahoo Finance
Is Capricor Therapeutics (CAPR) Still Attractive After A 72% One Year Share Price Jump - Yahoo Finance
Capricor Updates Deramiocel BLA Status After FDA Review of HOPE-3 Data - filmogaz.com
Capricor Therapeutics (CAPR) Valuation After FDA Requests HOPE-3 Data For Deramiocel Regulatory Review - Yahoo Finance
Capricor (CAPR) Plans February FDA Data Submission After 2% Stock Drop - Intellectia AI
CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think? - Stocktwits
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):